^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1293P - IMpower150: Updated efficacy analysis in patients with EGFR mutations
Published date:
09/14/2020
Excerpt:
In the randomised, Ph III IMpower150 study, first-line treatment (tx) with A + B + carboplatin and paclitaxel (CP) significantly prolonged PFS and OS compared with B + CP in patients (pts) with non-squamous NSCLC, including those with EGFR mutations….Exploratory analyses included OS in pts with EGFR mutations, pts with sensitising EGFR mutations (exon 19 deletions or L858R mutations) and pts with sensitising EGFR mutations who received prior tyrosine kinase inhibitors (TKIs)....With ≈ 20 additional months of follow-up, ABCP continued to show an OS benefit vs BCP in pts with sensitising EGFR mutations, including those who had prior tx failure with TKIs.
Secondary therapy:
carboplatin + paclitaxel
Trial ID:
Source:
Title:
A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR gene Un ensayo que explora la eficacia (qué tan bien funciona el tratamiento) y la tolerabilidad de la combinación de dos fármacos en investigación (atezolizumab y bevacizumab), cuando se administra junto con uno de dos tratamientos de quimioterapia diferentes, en pacientes con cáncer de pulmón de células no pequeñas y mutaciones específicas (cambios) en el gen EGFR
Excerpt:
...Patients who have received previous adjuvant or neoadjuvant chemotherapy are eligible if the date of last dose of treatment was at least 12 months before randomisation- Known EGFR mutations genotypes by tissue or ctDNA; patients with common mutations (L858R or Del19) and other rare mutations (e.g. S768I, G719X) are eligible- Measurable or evaluable disease by RECIST v1.1- Disease progression (during or after) or unacceptable side effects from prior treatment with at least one EGFR TKI (TKI washout period = 7 days). ...
Trial ID:
Source:
Title:
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
Excerpt:
...Known EGFR mutations genotypes by tissue or ctDNA, patients with common mutations (L858R or Del19) and other rare mutations (e.g....
